Gene link to higher rates of bowel cancer in men

June 1, 2012
Gene link to higher rates of bowel cancer in men

(Medical Xpress) -- Scientists have shown for the first time that one of the sex chromosomes is involved in the development of a cancer that can afflict both genders, according to a Cancer Research UK-funded study in Nature Genetics. The finding may help explain why men have higher rates of bowel cancer than women.

The international collaboration - led by The Institute of Cancer Research (ICR), the University of Oxford and Edinburgh University – was searching for changes to the DNA code that increase the risk of bowel cancer. For the first time, the scientists identified an alteration on the x-chromosome, one of two chromosomes that determine gender.

The ‘faulty’ region on the x-chromosome is linked to lower levels of a gene called SHROOM2 that controls how cells develop and take shape. Mutations in this gene have previously been linked to cancer.

The scientists have suggested that in women, the ‘faulty’ x-chromosome version is hidden by a normally-functioning version. But in men, who only have one copy of the x-chromosome, there is no normal version to mask this ‘faulty’ copy.

Co-lead researcher Professor Richard Houlston from The Institute of Cancer Research said: “To our knowledge, this is the first time that anyone has shown that one of the is involved in the development of a cancer that can afflict both sexes. This may help explain why bowel cancer is slightly more common in men. Ultimately, it could also help us target screening to those who are more at risk of the disease.”

The discovery of the x-chromosome link, along with a further two risk variants, brings the total number of regions on the genome found to increase the risk of bowel cancer to 20.  

To identify these genetic alterations the researchers studied SNPs (single nucleotide polymorphisms) - pieces of DNA that vary between individuals – from five previous international studies, looking for SNPs that were more common in cancer cases than healthy individuals.

The second variant found in this study is within the CDKN1A gene on chromosome 6. CDK1NA codes for a protein that is a key controller of a number of tumour suppressor pathways in the cell. It also blocks the creation of new strands of DNA which is needed in cancer cells as they grow and divide.   

The third variant discovered is located on chromosome 11, within a gene called POLD3. This gene plays a key role in two pathways that repair DNA damage, and which are defective in some bowel cancers.   

Bowel cancer is the third most common cancer in the UK - each year around 41,000 people are diagnosed with the disease, around 22,700 men and 18,400 women.  

Dr. Lesley Walker, director of cancer information at Cancer Research UK, said: “Cancer Research UK funded scientists have led the world in discovering that increase the risk of bowel cancer. This research adds to this understanding and shows how a range of genes could be behaving in , potentially leading to new treatments for the disease.”  

Explore further: Prostate cancer early warning protein detected

More information: Dunlop, M.G. et al Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk Nature Genetics (2012)

Related Stories

Prostate cancer early warning protein detected

May 31, 2012
(Medical Xpress) -- Scientists at the University have discovered a protein, only present in prostate cancer cells, that could be used as a marker to detect early signs of the disease.     

Poor men more likely to die from bowel cancer

November 7, 2011
(Medical Xpress) -- Deprived men are more likely to die from bowel cancer than men from the most affluent section of society, new research presented at the NCRI Cancer Conference in Liverpool this week shows.

Poor public awareness of bowel cancer

August 23, 2011
Britons have very low awareness of the signs and symptoms of bowel cancer – the third most common cancer in the UK and second largest cause of cancer deaths each year, new research shows.

Recommended for you

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.